Compare BioNTech SE - ADR (BNTX) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Global X SuperDividend ETF — how do they compare? BioNTech SE - ADR trades at $90.47 (market cap $22.86B), while Global X SuperDividend ETF trades at $24.88. The key difference: Global X SuperDividend ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SDIV | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $119.34 | $26.34 |
52-Week Low | $83.89 | $22.90 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
SDIV trades at $24.52, down 0.33% today, with a neutral technical signal overall. The ETF maintains a consistent dividend payout of $0.18 per share, with recent distributions in May and June 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster around $24-$25. Recent news highlights SDIV's appeal for income investors seeking diversification from tech-heavy portfolios.
SDIV offers investors exposure to high-yield global equities with minimal technology exposure, providing diversification benefits. The 9.29% yield remains attractive for income-focused portfolios, though the fund's heavy weighting in financials and energy sectors introduces sector concentration risks. Current technical positioning suggests limited near-term price movement potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
